254 related articles for article (PubMed ID: 37768439)
21. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
Getu AA; Tigabu A; Zhou M; Lu J; Fodstad Ø; Tan M
Mol Cancer; 2023 Mar; 22(1):43. PubMed ID: 36859240
[TBL] [Abstract][Full Text] [Related]
22. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P
Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969
[TBL] [Abstract][Full Text] [Related]
23. B7-H3 regulates anti-tumor immunity and promotes tumor development in colorectal cancer.
Zhang H; Zhu M; Zhao A; Shi T; Xi Q
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189031. PubMed ID: 38036107
[TBL] [Abstract][Full Text] [Related]
24. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
Yang S; Wei W; Zhao Q
Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
[TBL] [Abstract][Full Text] [Related]
25. B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
Pizon M; Schott DS; Pachmann U; Pachmann K
Int J Oncol; 2018 Nov; 53(5):2289-2299. PubMed ID: 30226585
[TBL] [Abstract][Full Text] [Related]
26. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
Yim J; Koh J; Kim S; Song SG; Ahn HK; Kim YA; Jeon YK; Chung DH
Eur J Cancer; 2020 Jul; 133():74-85. PubMed ID: 32447027
[TBL] [Abstract][Full Text] [Related]
27. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo.
Zhou Z; Yu X; Chen Y; Tan X; Liu W; Hua W; Chen L; Zhang W
Clin Transl Oncol; 2023 Apr; 25(4):1067-1079. PubMed ID: 36512305
[TBL] [Abstract][Full Text] [Related]
29. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.
Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ
Front Immunol; 2021; 12():757047. PubMed ID: 34675936
[TBL] [Abstract][Full Text] [Related]
30. Potential Therapeutic Targets of B7 Family in Colorectal Cancer.
Wang C; Feng H; Cheng X; Liu K; Cai D; Zhao R
Front Immunol; 2020; 11():681. PubMed ID: 32477326
[TBL] [Abstract][Full Text] [Related]
31. B7-H3 regulates KIF15-activated ERK1/2 pathway and contributes to radioresistance in colorectal cancer.
Ma Y; Zhan S; Lu H; Wang R; Xu Y; Zhang G; Cao L; Shi T; Zhang X; Chen W
Cell Death Dis; 2020 Oct; 11(10):824. PubMed ID: 33011740
[TBL] [Abstract][Full Text] [Related]
32. B7-H3 role in the immune landscape of cancer.
Castellanos JR; Purvis IJ; Labak CM; Guda MR; Tsung AJ; Velpula KK; Asuthkar S
Am J Clin Exp Immunol; 2017; 6(4):66-75. PubMed ID: 28695059
[TBL] [Abstract][Full Text] [Related]
33. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
[TBL] [Abstract][Full Text] [Related]
34. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
Zhang T; Jiang B; Zou ST; Liu F; Hua D
World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
[TBL] [Abstract][Full Text] [Related]
36. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
37. Clinical correlation of B7-H3 and B3GALT4 with the prognosis of colorectal cancer.
Zhang T; Wang F; Wu JY; Qiu ZC; Wang Y; Liu F; Ge XS; Qi XW; Mao Y; Hua D
World J Gastroenterol; 2018 Aug; 24(31):3538-3546. PubMed ID: 30131660
[TBL] [Abstract][Full Text] [Related]
38. B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors.
Rasic P; Jovanovic-Tucovic M; Jeremic M; Djuricic SM; Vasiljevic ZV; Milickovic M; Savic D
World J Gastrointest Oncol; 2021 Aug; 13(8):799-821. PubMed ID: 34457187
[TBL] [Abstract][Full Text] [Related]
39. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
[TBL] [Abstract][Full Text] [Related]
40. B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer.
Ingebrigtsen VA; Boye K; Tekle C; Nesland JM; Flatmark K; Fodstad O
Int J Cancer; 2012 Dec; 131(11):2528-36. PubMed ID: 22473715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
